SUNPHARMA Share Price, Analysis & Fundamentals

Despite strong analyst buy ratings and positive market momentum, Sun Pharma's recent QoQ earnings decline and sector-wide news without direct catalysts warrant caution.

The market exhibits a strong bullish trend, supported by positive momentum indicators, price trading above key EMAs, and supportive volume analysis, although valuations are at the higher end of their range.
Fundamental analysis reveals year-over-year revenue and profit growth, but a recent quarter-over-quarter decline in both metrics requires monitoring.
Analysts maintain a strongly bullish outlook, with 87.88% recommending Buy or Strong Buy, and this sentiment has been stable.
Ownership is concentrated, with promoters holding a significant stake, and there has been a mixed shift in institutional holdings (FIIs decreasing, DIIs increasing) quarter-over-quarter.
Recent events include SAHPRA approval for a generic semaglutide in South Africa and an upcoming Q1 FY2027 earnings announcement.
News highlights include sector-wide context on counterfeit drugs and trade pacts, with no direct company-specific catalysts identified.

The market shows a strong bullish trend with a trend alignment score of 3.
Momentum indicators are positive, with RSI at 67.08 and a bullish MACD crossover.
The price is trading above key Exponential Moving Averages (EMAs), indicating upward momentum.
Volatility is moderate with Bollinger Bands showing the price near the upper band, suggesting potential for continued upward movement or a short-term pause.
Volume analysis indicates accumulation and a rising On-Balance Volume (OBV) trend, supporting the bullish sentiment.

The market is exhibiting strong bullish characteristics across multiple technical indicators. The trend alignment score of 3 and the bullish MACD signal suggest a robust upward movement. The price is trading above its key EMAs, and the RSI is in the upper range, indicating strong positive momentum. Volume analysis, including accumulation and rising OBV, further supports the bullish outlook. While the price is approaching the upper Bollinger Band, which could signal a short-term consolidation, the overall trend remains strongly positive. Valuation metrics, such as P/E and P/B ratios, are at the higher end of their 6-month range, suggesting that the market may be fully valued, but this does not negate the current bullish technical setup.

The latest quarter (Mar 2026) reported revenue of ₹14,612 Cr and a net profit of ₹2,710 Cr.
Quarter-over-quarter, revenue decreased by -5.857% and net profit saw a decline of -19.846%.
Year-over-year, revenue grew by 12.756% and net profit increased by 25.812%.
Profitability shows a mixed trend with a YoY increase in net profit but a QoQ decrease.

Sun Pharma has received approval from SAHPRA for a generic semaglutide in South Africa, with a launch planned soon. Additionally, the company will announce its Q1 FY2027 results on July 31, 2026, followed by an earnings call.